Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low-Risk Therapy Clear all
Completed Phase 2Phase 3 Interventional

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

NCT03185143
View directory record Official record
Conditions
Migraine With and Without Aura
Interventions
Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

NCT00968760
View directory record Official record
Conditions
Lymphoma, B-cell Lymphoma
Interventions
Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion, IL-2, Carmustine, Etoposide, Cytarabine, Melphalan
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 8, 2026, 10:48 PM EDT
Withdrawn Not applicable Interventional

Focal Radiation Therapy for the Treatment of Low or Intermediate-Risk Prostate Cancer

NCT04399824
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 8, 2026, 10:48 PM EDT
Terminated Phase 2 Interventional Results available

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

NCT00126191
View directory record Official record
Conditions
Burkitt Lymphoma, Non-Hodgkins Lymphoma, Atypical Burkitt Lymphoma
Interventions
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Methotrexate, Leucovorin, Ifosfamide, Etoposide, Cytarabine, Mesna
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 8, 2026, 10:48 PM EDT
Withdrawn Phase 2 Interventional

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

NCT06005662
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

NCT01573754
View directory record Official record
Conditions
Porphyria Cutanea Tarda
Interventions
Hydroxychloroquine, Phlebotomy
Drug · Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma

NCT00895622
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
54 Gy radiotherapy, 60 Gy radiotherapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
74
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)

NCT00912223
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin
Interventions
Hematopoietic Stem Cell Transplant
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
21
States / cities
Duarte, California • La Jolla, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 8, 2026, 10:48 PM EDT
Terminated No phase listed Observational

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

NCT03554759
View directory record Official record
Conditions
Thrombocytopenia
Interventions
Avatrombopag
Drug
Lead sponsor
Sobi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2018 – 2019
U.S. locations
41
States / cities
Chandler, Arizona • Lancaster, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Sep 8, 2026, 10:48 PM EDT
Completed No phase listed Observational

Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia

NCT01726283
View directory record Official record
Conditions
Fruste Keratoconus, Risk of Ectasia
Interventions
Corneal Cross-Linking, Riboflavin
Device · Drug
Lead sponsor
Cxlusa
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2015 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Soft Tissue Biomechanical Behavior During Acupuncture in Low Back Pain

NCT00487266
View directory record Official record
Conditions
Low Back Pain
Interventions
Acupuncture
Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 8, 2026, 10:48 PM EDT
Withdrawn Phase 2 Interventional

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

NCT01280669
View directory record Official record
Conditions
Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
Interventions
Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 2 Interventional Results available

Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder

NCT00345605
View directory record Official record
Conditions
Argininosuccinic Aciduria, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
Interventions
Sodium Phenylbutyrate, Arginine
Drug
Lead sponsor
Brendan Lee
Other
Eligibility
5 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 8, 2026, 10:48 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris

NCT02796066
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Vehicle, TSN2898
Drug
Lead sponsor
Thesan Pharmaceuticals, Inc.
Industry
Eligibility
16 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
San Diego, California • Miami, Florida • High Point, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

NCT01858922
View directory record Official record
Conditions
Hodgkin Disease
Interventions
ABVE-PC, DECA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Sep 8, 2026, 10:48 PM EDT
Recruiting Phase 2 Interventional

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
28
States / cities
Berkeley, California • Duarte, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

NCT00002537
View directory record Official record
Conditions
Lung Cancer
Interventions
topotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations

NCT02124772
View directory record Official record
Conditions
Cancer
Interventions
Trametinib, Dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration

NCT02022501
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
DE-120
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Bakersfield, California • Beverly Hills, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Not applicable Interventional

Spaulding-Harvard Model System: Effects of Transcranial Direct Current Stimulation (tDCS) on Chronic Pain in Spinal Cord Injury

NCT01599767
View directory record Official record
Conditions
Spinal Cord Injury, Chronic Pain, Neuropathic Pain
Interventions
Transcranial direct current stimulation (tDCS)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 8, 2026, 10:48 PM EDT
Terminated Not applicable Interventional Results available

Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's

NCT02769000
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
10 GY in 5 daily fractions, 20 GY in 10 daily fractions
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
55 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 8, 2026, 10:48 PM EDT
Active, not recruiting Not applicable Interventional

Promoting Kangaroo Care for Preterm or Low Birthweight Infants in Rural India

NCT07231432
View directory record Official record
Conditions
Preterm Birth, Skin to Skin Contact, Low Birth Weight, Kangaroo Care
Interventions
Behavioral Interventions
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 8, 2026, 10:48 PM EDT
Completed Phase 2 Interventional

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

NCT02633163
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Low Dose Mesenchymal Stem Cells (MSCs), High Dose Mesenchymal Stem Cells (MSCs), Placebo Infusion
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 8, 2026, 10:48 PM EDT